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Background: Autism spectrum disorders and schizophrenia have been associated with an overlapping set of copy
number variant loci, but the nature and degree of overlap in copy number variants (deletions compared to
duplications) between these two disorders remains unclear.
Methods: We systematically evaluated three lines of evidence: (1) the statistical bases for associations of autism
spectrum disorders and schizophrenia with a set of the primary CNVs thus far investigated, from previous studies;
(2) data from case series studies on the occurrence of these CNVs in autism spectrum disorders, especially among
children, and (3) data on the extent to which the CNVs were associated with intellectual disability and
developmental, speech, or language delays. We also conducted new analyses of existing data on these CNVs in
autism by pooling data from seven case control studies.
Results: Four of the CNVs considered, dup 1q21.1, dup 15q11-q13, del 16p11.2, and dup 22q11.21, showed clear
statistical evidence as autism risk factors, whereas eight CNVs, del 1q21.1, del 3q29, del 15q11.2, del 15q13.3, dup
16p11.2, dup 16p13.1, del 17p12, and del 22q11.21, were strongly statistically supported as risk factors for
schizophrenia. Three of the CNVs, dup 1q21.1, dup 16p11.2, and dup 16p13.1, exhibited statistical support as risk
factors for both autism and schizophrenia, although for each of these CNVs statistical significance was nominal for
tests involving one of the two disorders. For the CNVs that were statistically associated with schizophrenia but were
not statistically associated with autism, a notable number of children with the CNVs have been diagnosed with
autism or ASD; children with these CNVs also demonstrate a high incidence of intellectual disability and
developmental, speech, or language delays.
Conclusions: These findings suggest that although CNV loci notably overlap between autism and schizophrenia,
the degree of strongly statistically supported overlap in specific CNVs at these loci remains limited. These analyses
also suggest that relatively severe premorbidity to CNV-associated schizophrenia in children may sometimes be
diagnosed as autism spectrum disorder.
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Recent studies of schizophrenia and autism spectrum
disorders have generated large suites of data, indicating
that each of these disorders is mediated in part by rare
copy number variants (CNVs), with substantial overlap
in copy number risk loci between the two disorders
[1-8]. These data are important because they provide
novel insights into both the neurodevelopmental causes
of autism spectrum disorders and schizophrenia, and the
relationship between the two disorders, a long-standing* Correspondence: crespi@sfu.ca
Department of Biosciences, Simon Fraser University, Burnaby, BC V5A 1 S6,
Canada
© 2012 Crespi and Crofts; licensee BioMed Ce
Creative Commons Attribution License (http:/
distribution, and reproduction in any mediumunresolved issue in psychiatry with direct implications
for etiology, diagnosis, the design of research programs,
and therapy.
Overlap in copy number loci or variants between
schizophrenia and autism spectrum disorders may have
several possible causes. First, CNV loci may overlap be-
tween the two disorders, but the actual variants asso-
ciated with each of them, such as deletions versus
duplications of the same region, or different specific
regions, may vary within and between the two disorders.
Examples of genes involved in CNVs for this category in-
clude APBA2, CNTNAP2, NRXN1, PARK2, and
SHANK3 [9-13].ntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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among individuals with schizophrenia or autism
spectrum disorders, or statistically supported as a risk
factor for both disorders. Such findings implicate over-
lapping genetic risk factors and shared etiology, which
has been postulated to help explain shared phenotypes,
mainly deficits and abnormalities in social development
and language. This interpretation, however, runs counter
to a large body of non-genetic evidence that differenti-
ates autism spectrum disorders from schizophrenia
[14-17], including an exclusionary condition with regard
to autism in DSM-IV. How can this apparent incongruity
be resolved? One possible explanation is that shared
phenotypes of autism spectrum disorders and schizo-
phrenia could be underlain by shared CNV risk fac-
tors. This hypothesis has yet to be addressed directly
and requires more detailed information on genotype-
phenotype relations than is currently available. By con-
trast, an alternative yet non-exclusive hypothesis, origin-
ally suggested by Eliez [18] in the context of 22q11.2
deletions, is that for some loci, sharing of CNVs between
schizophrenia and autism is more apparent than real, be-
cause of false-positive diagnoses of relatively severe,
CNV-associated premorbidity to schizophrenia as autism
or autism spectrum disorder [19]. The presence of such
false positives is predicated on the supposition that aut-
ism or autism spectrum disorders and schizophrenia
represent distinct conditions with partially overlapping
childhood psychological deficits and abnormalities,
which are due to different neurodevelopmental causes.
In this article, data from CNV studies of schizophrenia
and autism spectrum disorders are used to evaluate al-
ternative hypotheses [20] for the relationship between
these disorders that follow from these considerations,
and to evaluate the plausibility of the hypothesis of diag-
noses of premorbidity to schizophrenia as an autism
spectrum disorder in individuals with CNVs. The pri-
mary alternative hypotheses considered are: (1) schizo-
phrenia and autism spectrum disorders as conditions
that are genetically distinct with regard to their associa-
tions with CNVs; and (2) schizophrenia and autism
spectrum disorders as overlapping with regard to their
associations with CNVs. Such overlap may, however, ei-
ther be real (a true positive) or only apparent and due
substantially to false positive diagnoses of premorbidity
to schizophrenia as an autism spectrum disorder. These
hypotheses make alternative, more or less exclusive pre-
dictions (Table 1) that are evaluated using data from
CNVs in these two disorders, and data on other pheno-
types and diagnoses associated with the CNVs.
Methods
CNVs were included for analysis if they met three cri-
teria: (1) previous evidence for statistical association ofthe CNV with schizophrenia, autism, or both disorders;
(2) reports of the CNV in both conditions, from case
control, family-based, or case series studies (CNV studies
based on ascertainment of a range of childhood condi-
tions, followed by focused analysis on one or more spe-
cific CNVs); and (3) sufficient information on
phenotypes associated with the CNVs, especially intellec-
tual disability and developmental, speech or language
delay, to assess its effects on childhood development,
bearing in mind how individuals were ascertained.
Genomic coordinates of the CNVs considered here
were defined as in the salient publications (e.g., [21])
and as described below. A pooled analysis was also
conducted to test for the focal CNVs as statistically
based autism risk factors; this analysis included data
from all CNV studies that focused on autism, across
multiple loci, using case control or case unaffected
sibling designs: Table 1 in Sebat et al. [22], Supplemen-
tary Table 2 in Szatmari et al. [23], Table S2 in Christian
et al. [24], Table 3 in Marshall et al. [25], Table 1 and
pers. comm. in Glessner et al. [26], Supplementary
Tables 2, 6, and 8 in Pinto et al. [27], and Table 3 in San-
ders et al. [28]. Overlap among studies in autism cases
for the AGRE and the AGP data was accounted for in
discernment of cases and analysis (i.e., autism and aut-
ism spectrum individuals with a given CNV were
counted only once). Overall, this analysis included 5,530
cases and 7190 controls. Any overlap between studies in
probands who did not harbor CNVs would bias case
control analyses against rejection of the null hypothesis
(of no association), and thus render the tests performed
more conservative. Additional caveats regarding the
pooled case control analysis for autism conducted here,
and the results from other authors presented in Table 2,
include the lack of report of all observed CNVs in some
studies [26], possible unobserved overlap among indivi-
duals in control groups, and the uses of different tech-
nology platforms of varying sensitivities for CNV
detection and analysis.
Results
Four of the CNVs, dup 1q21.1, dup 15q11-q13, del
16p11.2, and dup 22q11.21, show clear statistical evi-
dence as autism risk factors, whereas the other eight
CNVs considered here, del 1q21.1, del 3q29, del 15q11.2,
del 15q13.3, dup 16p11.2, dup 16p13.1, del 17p12, and
del 22q11.21, are well supported as risk factors for
schizophrenia (Table 2). Three CNVs, dup 1q21.1, dup
16p11.2, and dup16p13.1, exhibit statistical support as
risk factors for both autism and schizophrenia, although
in each case statistical significance is nominal for one of
the two conditions (dup 1q21.1 in schizophrenia,
p= 0.02; dup 16p11.2 in autism, p= 0.025 in the pooled
case control analysis; dup 16p13.1 in autism, p= 0.023 in
Table 1 Predictions for the distributions of autism or ASD and schizophrenia in children and adults under different
models of CNV specificity to particular disorders
MODEL 1: AUTISM or ASD and schizophrenia as separate disorders
MODEL 1a: AUTISM OR ASD ONLY
Child Adult Comments
CNV is autism risk factor only Autism or ASD Autism or ASD; no
schizophrenia
ASD traits, but no schizophrenia
spectrum traits, in adults
MODEL 1b: SCHIZOPHRENIA ONLY
Child Adult Comments
CNV is schizophrenia risk factor Non-clinical or mild
premorbidity; no autism or ASD
Schizophrenia;
no autism or ASD
Possibe schizophrenia spectrum
traits in individuals with CNV but
no schizophrenia diagnosis
MODEL 2: ASD and schizophrenia as apparently overlapping disorders
MODEL 2a: AUTISM OR ASD AND SCHIZOPHRENIA; TRUE OVERLAP
Child Adult Comments
CNV is risk factor for both autism or
ASD and schizophrenia
Autism or ASD Schizophrenia or
autism or ASD
Traits overlapping ASD, autism and
schizophrenia, such as sociality and
language deficits/abnormalities, are
prominent
MODEL 2b: SCHIZOPHRENIA ONLY; AUTISM OR ASD IS FALSE POSITIVE
Child Adult Comments
CNV is schizophrenia risk factor only; autism
or ASD diagnoses are false positives
‘Autism or ASD’ (actually
premorbidity to schizophrenia)
Schizophrenia;
no autism or ASD
‘ASD’ children have adult relatives with
schizophrenia or schizophrenia spectrum;
‘ASD’ is commonly PDD-NOS; child ‘ASD’
phenotypes resemble schizophrenia
premorbid phenotypes that are relatively
severe
Crespi and Crofts Journal of Neurodevelopmental Disorders 2012, 4:15 Page 3 of 9
http://www.jneurodevdisorders.com/content/4/1/15the analysis by Table 2 in Hannes et al. [49]). Details
regarding all of the relevant studies, for each CNV locus,
are presented in Additional file 1.
For all of the CNV risk factors for schizophrenia, case
reports and case series demonstrate that multiple chil-
dren with the CNV have been diagnosed with autism,
ASD, autistic features, intellectual disability, develop-
mental, speech, or language delays, and/or multiple con-
genital anomalies (Table 2 and Additional file 1). Such
case studies have generally not, however, evaluated the
statistical significance of the CNV as an autism spectrum
condition risk factor.
Discussion
With regard to the predictions of the different models
in Table 1, three autism-associated CNVs, dup 15q11-
q13, del 16p11.2, and dup 22q11.21, appear to fit with
Model 1a, in that very few or no cases of schizophre-
nia have been reported among individuals with these
CNVs and they show a lack of statistical evidence of
being schizophrenia risk factors. Evidence regarding
the associations of three CNVs, dup 1q21.1, dup
16p11.2, and dup 16p13.1, with autism and schizophre-
nia risk suggests that they may fit with Model 2a of
true overlap, although the nominal nature of one of
the statistical associations, for each CNV, indicates that
additional data are needed for robust interpretation andexclusion of Model 2b. In addition, for dup 16p13.1,
evidence of an association with autism comes from a
single analysis that includes only three autism cases
with the CNV [49], whereas analysis of the pooled data
from seven case control studies provides no evidence of
association.
The largest number of CNVs (deletions of 1q21.1,
3q29, 15q11.2, 15q13.3, 17p12, and 22q11.2) appears to
fit Model 2b of schizophrenia risk with possible false-
positive diagnoses of ASDs in childhood. Such putative
false-positive interpretations are based on a combination
of four lines of evidence: (1) strong statistical evidence
from studies of schizophrenia for the CNV as a risk fac-
tor in this disorder; (2) reports of the CNV in some indi-
viduals with ASD from large-scale, case control CNV
studies of ASD or autism, but with lack of its documen-
tation as a statistically based risk factor for ASD or aut-
ism from case control studies; (3) reports of the CNV in
ASD or autism cases from case series and case report-
based studies that are designed and presented in non-
statistical contexts; and (4) the presence, among children
with the CNV, of a high frequency of some combination
of intellectual disability, developmental delay, or speech
or language delay [72], conditions that may represent
manifestations of premorbidity to schizophrenia that can
contribute to ascertainment and diagnoses of ASDs in
children [18,73,74].
Table 2 Data on statistical significance, numbers of cases (in boldface parentheses), and case descriptions, for CNVs
that have been reported in both autism and schizophrenia
CNV Number
autism
# cases (refs) 1
Number
controls
# cases (refs) 1
p, autism risk,
pooled data1
p, autism risk,
prev. studies
(# cases) (refs)
p, schizo. risk,
prev. studies
(# cases) (refs) 2
Autism, ASD, ID,
delays, in case
reports, series (refs)3
Model
supported
del 1q21.1 1 [23] 0 0.43 0.029 (1) [4,29] 8.5 × 10-6 (20)[30] Yes [29,31] 2b
dup 1q21.1 7 [23,27,28] 0 0.0029 9 × 10-5 (3)[4,29] 0.02 (11)[30] Yes [29,31] 2a or 2b
del 3q29 1 [28] 0 0.43 0.0004 (7)[30] Yes [32-34] 2b
del 15q11.2 2 [27] 0 0.19 4.46 × 10-8 (49)[3] Yes [35-38] 2b
dup 15q11-q13
(BP2-BP3)
20 [23,24 26–28] 0 <0.0001 4 × 10-4, (6)[28];
1 × 10-5, (13)[26]
0.10 (2)[7] Yes [7,39,40] 1a
del 15q13.3 3 [27,28] 0 0.082 6.9 × 10-7 (21)[30] Yes [41-43] 2b
del 16p11.2 15 [22,25-28] 4 (26) 0.0015 5 × 10-29 (14)[28];
0.044 (4)[44]
0.88 (4)[30] Yes [45-48] 1a
dup 16p11.2 10 [25-28] 4 (26) 0.0246 2 × 10-5 (5)[28] 2.6 × 10-8 (31)[30] Yes [45,47] 2a or 2b
dup 16p13.1 0 0 ns 0.023 (3)[49] 0.00001 (12)[50] Yes [49,51,52] 2a or 2b
del 17p12 2 [28] 0 0.19 0.58, 0.14 (5) [53]4 0.0147 (4) [53] Yes [53-55] 2b
del 22q11.21 2 [27,28] 0 0.19 0.11 (3)[28] 7.3 × 10-13 (35)[30] Yes [19,56-62] 2b
dup 22q11.21 9 [24-27] 0 0.00055 0.0218 (5)[26] Not tested in [4] or
[30]; too few cases
of schizophrenia
Yes [63-70] 1a
See Additional file 1 for details.
1 Case control data from Sebat et al. [22], Szatmari et al. [23], Christian et al. [24], Marshall et al. [25], Glessner et al. [26], Pinto et al. [27], and Sanders et al. [28].
Details are provided in Additional file 1.
Fisher's exact test was used.
2 Most recent analysis, meta-analysis, or pooled-data analysis.
3 Details of these studies are provided in Additional file 1. See also Cooper et al. [71], Kaminsky et al. [21], and Sahoo et al. [72]. "Yes" refers to the presence of
autism, ASD, or 'autistic features' among one or more individuals in these reports.
4 Tests involve autism cases only, discovery and follow-up samples. See Additional file 1 for details.
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spectrum disorder might be expected in CNV studies for
several additional reasons, from previous studies:
1. Schizophrenia involves well-documented
premorbidity, in a substantial proportion of cases,
which centers on developmental, social, and
language deficits [75-78]. In children, premorbidity
to schizophrenia most commonly involves ‘negative’
symptoms including deficits in social interaction
[79,80], which can overlap with symptoms of autism
spectrum disorders [81-85]. Mild to borderline
intellectual disability in individuals with
schizophrenia is also associated with a higher
incidence of negative, compared to positive,
symptoms by meta-analysis [86], although this study
did not consider effects on premorbid phenotypes.
Most of the overlap in symptoms between ASDs and
schizophrenia premorbidity appears to involve
deficits, delays, or generalized abnormalities, rather
than the definitive presence of specific biological or
psychological phenotypes. Among all autism
spectrum disorders, PDD-NOS is the most
commonly diagnosed [87,88]. Such cases usually fail
to reach the threshold for autism because of lack of
fit to the criteria for restricted interests andrepetitive behavior [89], which is also the ASD
criterion least likely to be represented in
premorbidity to schizophrenia. Premorbidity to
schizophrenia is also more severe among males than
females [11,80,90], which is concordant with the
strong male bias found in autism spectrum disorders
[91];
2. Compared to disease-associated SNPs, disease-
associated CNVs tend to be rare, more-highly
penetrant, syndromic genetic risk factors [8,92,93].
Their deleterious effects on early neurodevelopment
might thus be expected to be relatively severe, such
that childhood premorbidity, for individuals with
schizophrenia-risk CNVs, might be especially
prevalent and pronounced compared to individuals
without schizophrenia-risk CNVs. A recent study by
Sahoo et al. [72] provides evidence consistent with
such premorbidity, in that of 38,779 individuals
(predominantly children) referred mainly for
developmental delay, intellectual disability, autism
spectrum disorders, or multiple congenital
anomalies, 704 exhibited one of seven CNVs (del
1q21.1, dup 1q21.1, del 15q11.2, del 15q13.3, dup
16p11.2, dup 16p13.11, or del 22q11.2) that has been
statistically associated with schizophrenia in studies
of adults [30,50].
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of individuals diagnosed with autism spectrum
disorders in early to middle childhood, and
schizophrenia in late childhood, adolescence, or
early adulthood [11,94-100]. Despite these
associations, individuals with ASD are apparently
not at overall higher risk of later developing
schizophrenia [101,102]. Moreover, autism and ASD
tend to show familial aggregation of their diagnoses
and phenotypes [16,103-105], largely separate from
the strong familial aggregation found for
schizophrenia [106-108]. A simple hypothesis for
explaining these findings would be that sequential
diagnoses in the same individuals of ASD (in
childhood) and schizophrenia (in adulthood) are
sometimes mediated by rare, penetrant
schizophrenia risk factors (such as CNVs) that cause
relatively severe premorbidity [11]. Direct evidence
regarding this hypothesis comes from Addington
and Rapoport [109], who showed that individuals
with childhood-onset schizophrenia mediated by
schizophrenia-associated CNVs were more likely to
exhibit premorbidity to schizophrenia in the form of
developmental delays (p= 0.0001) and may have
been more likely to exhibit diagnoses of a PDD
(p= 0.10) compared to such children lacking these
CNVs. Additional evidence comes from studies by
Ingason et al. [7] and Chen et al. [110], who each
reported sequential diagnoses of autism spectrum
disorder in childhood and schizophrenia in
adulthood among an individual with such alterations
(respectively, a duplication of 15q11-q13 and a
balanced translocation disrupting GNB1L, a gene in
the 22q11.2 deletion region).
Evaluation of whether ASD diagnoses represent false
positives for individuals with schizophrenia-associated
CNVs would require longitudinal studies of the indivi-
duals involved. Resolution of this question would also
benefit from studies of non-clinical individuals bearing
risk CNVs, analyses of autism and schizophrenia endo-
phenotypes among individuals with risk CNVs, and stud-
ies that focus on the differential diagnosis of autism
spectrum disorders in relation to schizophrenia premor-
bidity in children [11,111-117].
An alternative interpretation to the false-positive hy-
pothesis for diagnoses of ASD among children with
schizophrenia-associated CNVs is that such ASD diag-
noses are true positives that are compatible with possible
later diagnoses of the same individual with schizophrenia
[56,99]. Under this interpretation, diagnoses of ASD in
children who develop schizophrenia as adolescents or
adults would reflect developmental stages, with schizo-
phrenia as the final pathway [118]. By contrast, otherASD cases would fit the classic criteria derived from
Kanner [119], Asperger [120], and Rutter [16,17,121],
which consider autism as a lifelong condition present
from early childhood. Whether or not childhood pre-
morbidity to schizophrenia should be considered an
ASD remains an open question, the resolution of which
depends in part on the degree to which the causes and
phenotypes of ASD in schizophrenia premorbidity over-
lap with the causes and phenotypes of other cases of
ASD.
Conclusions
One of the primary implications of these results is that
hypotheses of autism and schizophrenia sharing sub-
stantial genetic etiology with regard to specific CNVs
are not strongly supported by the empirical data, and
appear to be based in large part on non-statistical evi-
dence from case reports and case series, combining of
duplications with deletions for statistical analyses, very
small numbers of cases, or pooling of autism or ASD
with other diagnoses (such as developmental delay or
intellectual disability), which prevents inference con-
cerning which, if any, of the conditions are associated
with the focal CNV [1,28,53,122,123]. Additional studies
that focus strictly on autism or ASD and schizophrenia
for specific CNVs, that take account of childhood pre-
morbidity to schizophrenia as a possible confounding
factor, should help to clarify the relationship between
these disorders.Additional file
Additional file 1: Association testing of copy number variants in
schizophrenia and autism spectrum disorders.
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